$0.05 EPS Expected for First Choice Healthcare Solutions (FCHS); ARGOS THERAPEUTICS (ARGS) Sentiment Is 2.7

July 27, 2017 - By Adrian Mccoy

Analysts expect First Choice Healthcare Solutions Inc (OTCMKTS:FCHS) to report $0.05 EPS on August, 21.They anticipate $0.04 EPS change or 400.00% from last quarter’s $0.01 EPS. FCHS’s profit would be $1.34 million giving it 7.05 P/E if the $0.05 EPS is correct. After having $0.01 EPS previously, First Choice Healthcare Solutions Inc’s analysts see 400.00% EPS growth. About 14,700 shares traded. First Choice Healthcare Solutions Inc (OTCMKTS:FCHS) has 0.00% since July 27, 2016 and is . It has underperformed by 16.70% the S&P500.

Argos Therapeutics, Inc. is an immuno-oncology company. The company has market cap of $11.77 million. The Firm is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. It currently has negative earnings. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

First Choice Healthcare Solutions, Inc. is focused on building a network of localized, integrated healthcare systems, which consists of non-physician-owned medical centers of excellence. The company has market cap of $37.79 million. The medical centers of excellence concentrate on treating patients in various specialties, including Orthopedics, Spine Surgery, Neurology, Interventional Pain Management, and related diagnostic and ancillary services in markets throughout the Southeastern United States. It currently has negative earnings. The Firm operates in healthcare services and real estate divisions through its subsidiaries.

Wall Street Associates holds 0.27% of its portfolio in Argos Therapeutics Inc for 82,850 shares. Wasatch Advisors Inc owns 3.25 million shares or 0.24% of their US portfolio. Moreover, Altrinsic Global Advisors Llc has 0.03% invested in the company for 172,505 shares. The Texas-based Bridgeway Capital Management Inc has invested 0.01% in the stock. American International Group Inc, a New York-based fund reported 6,131 shares.

Analysts await Argos Therapeutics Inc (NASDAQ:ARGS) to report earnings on August, 9. They expect $-0.13 earnings per share, up 72.92% or $0.35 from last year’s $-0.48 per share. After $-0.58 actual earnings per share reported by Argos Therapeutics Inc for the previous quarter, Wall Street now forecasts -77.59% EPS growth.

Ratings analysis reveals 0 of Argos Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Argos Therapeutics, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. ARGS was included in 2 notes of analysts from February 22, 2017. The rating was downgraded by JMP Securities to “Mkt Perform” on Wednesday, February 22. FBR Capital downgraded the stock to “Mkt Perform” rating in Wednesday, February 22 report.